Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
STAMPEDE Investigators, McPhail N, McKinna F, Malik Z, Lester J, Hoskin P, Hingorani M, Gray E, Gale J, Ferguson C, Chakraborti P, Money-Kyrle J, O'Sullivan J, Sydes M, Parmar M, Zarkar A, Wylie J, Wagstaff J, Thomas C, Srihari N, Robinson A, Protheroe A, Parikh O, Brock S, Bowen J, Matheson D, Jones R, Gilson C, Amos C, Ritchie A, Dearnaley D, Mason M, Clarke N, Spears M, de Bono J, Millman R, Attard G, Birtle A, Aung S, Adab F, Brawley C, Berthold D, Russell J, Parker C, Gillessen Sommer S, Cross W, Chowdhury S, James N. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017; 377:338-351.
Jun 3, 2017Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Jun 3, 2017N Engl J Med 2017; 377:338-351
STAMPEDE Investigators, McPhail Neil, McKinna Fiona, Malik Zafar I, Lester Jason F, Hoskin Peter J, Hingorani Mohan, Gray Emma, Gale Joanna, Ferguson Catherine, Chakraborti Prabir, Money-Kyrle Julian, O'Sullivan Joe, Sydes Matthew R, Parmar Mahesh K B, Zarkar Anjali, Wylie James, Wagstaff John, Thomas Carys, Srihari Narayanan N, Robinson Angus, Protheroe Andrew, Parikh Omi, Brock Susannah, Bowen Jo, Matheson David, Jones Rob J, Gilson Clare, Amos Claire L, Ritchie Alastair W S, Dearnaley David P, Mason Malcolm D, Clarke Noel W, Spears Melissa R, de Bono Johann S, Millman Robin, Attard Gerhardt, Birtle Alison J, Aung San, Adab Fawzi, Brawley Chris, Berthold Dominik R, Russell J Martin, Parker Christopher C, Gillessen Sommer Silke, Cross William R, Chowdhury Simon, James Nicholas D
First international consensus conference on standardization of oncoplastic breast conserving surgery
Weber W, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer J, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Bjelic-Radisic V, Dubsky P, Fitzal F, Soysal S, El-Tamer M, Sacchini V, Knauer M, Tausch C, Hauser N, Günthert A, Harder Y, Kappos E, Schwab F, Kurzeder C. First international consensus conference on standardization of oncoplastic breast conserving surgery. Breast Cancer Res Treat 2017; 165:139-149.
Jun 3, 2017First international consensus conference on standardization of oncoplastic breast conserving surgery
Jun 3, 2017Breast Cancer Res Treat 2017; 165:139-149
Weber Walter P, Reitsamer Roland, Koller Rupert, Heil Jörg, Hahn Markus, Blohmer Jens-Uwe, Hoffmann Jürgen, Solbach Christine, Heitmann Christoph, Gerber Bernd, Haug Martin, Bjelic-Radisic Vesna, Dubsky Peter, Fitzal Florian, Soysal Savas D, El-Tamer Mahmoud, Sacchini Virgilio, Knauer Michael, Tausch Christoph, Hauser Nik, Günthert Andreas, Harder Yves, Kappos Elisabeth A, Schwab Fabienne, Kurzeder Christian
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
Ess S, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. Eur J Cancer Care (Engl) 2017
May 30, 2017Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
May 30, 2017Eur J Cancer Care (Engl) 2017
Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum Wolfram, Früh Martin
Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity
Hamzic S, Kummer D, Milesi S, Mueller D, Jörger M, Aebi S, Amstutz U, Largiader C. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017; 102:796-804.
May 30, 2017Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity
May 30, 2017Clin Pharmacol Ther 2017; 102:796-804
Hamzic S, Kummer D, Milesi S, Mueller D, Jörger Markus, Aebi S, Amstutz U, Largiader C R
Spotlight on pomalidomide: could less be more?
Zander T, Aebi S, Pabst T, Renner C, Driessen C. Spotlight on pomalidomide: could less be more?. Leukemia 2017; 31:1987-1989.
May 22, 2017Spotlight on pomalidomide: could less be more?
May 22, 2017Leukemia 2017; 31:1987-1989
Zander T, Aebi S, Pabst T, Renner C, Driessen Christoph
RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
Gachechiladze M, Škarda J, Soltermann A, Jörger M. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. Int J Cancer 2017; 141:1286-1294.
May 19, 2017RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies
May 19, 2017Int J Cancer 2017; 141:1286-1294
Gachechiladze Mariam, Škarda Josef, Soltermann Alex, Jörger Markus
Monitoring of Patients’ Needs, Professional Triggers and Delivered Basic Palliative Care Interventions in Routine Inpatient and Ambulatory of Advanced Incurable Cancer Patients:
Domeisen Benedetti F, Blum D, Attoun-Knobel S, Schmidt M, Fringer A, Strasser F (2017). Monitoring of Patients’ Needs, Professional Triggers and Delivered Basic Palliative Care Interventions in Routine Inpatient and Ambulatory of Advanced Incurable Cancer Patients: - Phase I Complex Intervention Study.
May 18, 2017Monitoring of Patients’ Needs, Professional Triggers and Delivered Basic Palliative Care Interventions in Routine Inpatient and Ambulatory of Advanced Incurable Cancer Patients:
May 18, 2017EAPC Congress
Domeisen Benedetti Franzisca, Blum David, Attoun-Knobel Suzanne, Schmidt Mary Helen, Fringer André, Strasser Florian
Feasibility Study of the care pathway checklist (CPCL) for palliative care interventions (PCIs) delivered by oncologists in routine care
Mosoiu D, Achimas P, Domeisen Benedetti F, Rahnea G, Poroch V, Grigorescu A, Curca R, Schmidt M, Magayakalbermatten N, Groza M, Strasser F (2017). Feasibility Study of the care pathway checklist (CPCL) for palliative care interventions (PCIs) delivered by oncologists in routine care.
May 18, 2017Feasibility Study of the care pathway checklist (CPCL) for palliative care interventions (PCIs) delivered by oncologists in routine care
May 18, 2017EAPC Congress
Mosoiu D., Achimas P., Domeisen Benedetti Franzisca, Rahnea G., Poroch V., Grigorescu A., Curca R., Schmidt Mary Helen, Magayakalbermatten N, Groza M., Strasser Florian
Patient-perceived Needs, Gaps in Service Delivery, and Quality Indicators in Seven Dimensions of Palliative Interventions (PCIs) in Cancer Care
Magayakalbermatten N, Achimas P, Domeisen Benedetti F, Rahnea G, Poroch V, Mosoiu D, Groza M, Grigorescu A, Curca R, Schmidt M, Strasser F (2017). Patient-perceived Needs, Gaps in Service Delivery, and Quality Indicators in Seven Dimensions of Palliative Interventions (PCIs) in Cancer Care. Presented at: EAPC Congress, Madrid
May 18, 2017Patient-perceived Needs, Gaps in Service Delivery, and Quality Indicators in Seven Dimensions of Palliative Interventions (PCIs) in Cancer Care
May 18, 2017EAPC Congress
Magayakalbermatten N, Achimas P., Domeisen Benedetti Franzisca, Rahnea G., Poroch V., Mosoiu D., Groza M., Grigorescu A., Curca R., Schmidt Mary Helen, Strasser Florian
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Bartlett J, Rea D, Dowsett M, Cuzick J, Viale G, Forbes J, Brookes C, Van de Velde C, Putter H, Seynaeve C, Thürlimann B, Dell'Orto P, Mallon E, Sestak I, Regan M, Ahmed I. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer 2017; 79:129-138.
May 8, 2017HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
May 8, 2017Eur J Cancer 2017; 79:129-138
Bartlett John M S, Rea Daniel W, Dowsett Mitchell, Cuzick Jack, Viale Giuseppe, Forbes John F, Brookes Cassandra L, Van de Velde Cornelis J H, Putter Hein, Seynaeve Caroline, Thürlimann Beat, Dell'Orto Patrizia, Mallon Elizabeth A, Sestak Ivana, Regan Meredith M, Ahmed Ikhlaaq
Multiple primary tumours: challenges and approaches, a review
Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017; 2:e000172.
May 2, 2017Multiple primary tumours: challenges and approaches, a review
May 2, 2017ESMO Open 2017; 2:e000172
Vogt Alexia, Schmid Sabine, Heinimann Karl, Frick Harald, Herrmann Christian, Cerny Thomas, Omlin Aurelius
Bevacizumab: Zankapfel der Glioblastomtherapie
Hundsberger T, Weller M. Bevacizumab: Zankapfel der Glioblastomtherapie. Praxis (Bern 1994) 2017; 106:415-420.
Apr 27, 2017Bevacizumab: Zankapfel der Glioblastomtherapie
Apr 27, 2017Praxis (Bern 1994) 2017; 106:415-420
Hundsberger Thomas, Weller Michael
CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
Ettl J, Huober J, Luftner D, Marme F, Würstlein R. CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer. Breast Care (Basel) 2017; 12:118-120.
Apr 26, 2017CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
Apr 26, 2017Breast Care (Basel) 2017; 12:118-120
Ettl Johannes, Huober Jens, Luftner Diana, Marme Frederik, Würstlein Rachel
Angiogenesis inhibitors in tackling recurrent glioblastoma
Hundsberger T, Reardon D, Wen P. Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther 2017
Apr 24, 2017Angiogenesis inhibitors in tackling recurrent glioblastoma
Apr 24, 2017Expert Rev Anticancer Ther 2017
Hundsberger Thomas, Reardon David A, Wen Patrick Y
Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Ribi K, Rondeau S, Hitz F, Mey U, Enoiu M, Pabst T, Stathis A, Fischer N, Clough-Gorr K. Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma. Support Care Cancer 2017; 25:2833-2842.
Apr 13, 2017Cancer-specific geriatric assessment and quality of life: important factors in caring for older patients with aggressive B-cell lymphoma
Apr 13, 2017Support Care Cancer 2017; 25:2833-2842
Ribi Karin, Rondeau Stephanie, Hitz Felicitas, Mey Ulrich, Enoiu Milica, Pabst Thomas, Stathis Anastasios, Fischer Natalie, Clough-Gorr Kerri M
Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival
Viehl C, Oertli D, Sauter G, Terracciano L, Langer I, Banz V, Ramser M, Rosenthal R, Dell-Kuster S, Gueller U, Weixler B, Zuber M. Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival. Cancer Med 2017; 6:918-927.
Apr 12, 2017Presence of bone marrow micro-metastases in stage I-III colon cancer patients is associated with worse disease-free and overall survival
Apr 12, 2017Cancer Med 2017; 6:918-927
Viehl Carsten T, Oertli Daniel, Sauter Guido, Terracciano Luigi, Langer Igor, Banz Vanessa, Ramser Michaela, Rosenthal Rachel, Dell-Kuster Salome, Gueller Ulrich, Weixler Benjamin, Zuber Markus
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Burmeister K, Tornillo L, Piscuoglio S, Ng C, Köberle D, Lehmann F, Moosmann P, Horber D, Jochum W, Grobholz R, Perrina V, Matter M, Eppenberger-Castori S, Andreozzi M, Quagliata L, Terracciano L. Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes. PloS one 2017; 12:e0175563.
Apr 12, 2017Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes
Apr 12, 2017PloS one 2017; 12:e0175563
Burmeister Katharina, Tornillo Luigi, Piscuoglio Salvatore, Ng Charlotte K Y, Köberle Dieter, Lehmann Frank, Moosmann Peter, Horber Daniel, Jochum Wolfram, Grobholz Rainer, Perrina Valeria, Matter Matthias S, Eppenberger-Castori Serenella, Andreozzi Mariacarla, Quagliata Luca, Terracciano Luigi M
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Rosell R, Shah R, Porta R, Majem M, Gómez-Codina J, Camps C, Thomas M, Rauch D, Barlesi F, Hanrahan E, Kammler R, Stahel R, Molina-Vila M, Shames D, Tam R, Karachaliou N, Kassapian M, Rabaglio M, Ruepp B, Coate L, Puente J, Aix S, Palmero R, Massutí B, Peters S, Gautschi O, Curioni-Fontecedro A, Felip E, Dafni U, Carcereny E, Früh M, Reguart N, Froesch P, Favaretto A, Bidoli P, Cuffe S, Kotsakis A, Popat S, Pless M, BELIEF collaborative group. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017; 5:435-444.
Apr 10, 2017Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Apr 10, 2017Lancet Respir Med 2017; 5:435-444
Rosell Rafael, Shah Riyaz, Porta Rut, Majem Margarita, Gómez-Codina Jose, Camps Carlos, Thomas Michael, Rauch Daniel, Barlesi Fabrice, Hanrahan Emer, Kammler Roswitha, Stahel Rolf A, Molina-Vila Miguel A, Shames David S, Tam Rachel, Karachaliou Niki, Kassapian Marie, Rabaglio Manuela, Ruepp Barbara, Coate Linda, Puente Javier, Aix Santiago Ponce, Palmero Ramon, Massutí Bartomeu, Peters Solange, Gautschi Oliver, Curioni-Fontecedro Alessandra, Felip Enriqueta, Dafni Urania, Carcereny Enric, Früh Martin, Reguart Noemí, Froesch Patrizia, Favaretto Adolfo, Bidoli Paolo, Cuffe Sinead, Kotsakis Athanasios, Popat Sanjay, Pless Miklos, BELIEF collaborative group
Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
Siano M, Licitra L, Locati L, Miceli R, Granata R, Bergamini C, Alfieri S, Cau M, Resteghini C, Infante G, Bossi P. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Oral Oncol 2017; 69:33-37.
Apr 9, 2017Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy
Apr 9, 2017Oral Oncol 2017; 69:33-37
Siano Marco, Licitra Lisa, Locati Laura, Miceli Rosalba, Granata Roberta, Bergamini Cristiana, Alfieri Salvatore, Cau Maria Chiara, Resteghini Carlo, Infante Gabriele, Bossi Paolo
Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force
Prior J, Gillessen Sommer S, Wirth M, Dale W, Aapro M, Oyen W. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. Eur J Cancer 2017; 77:127-139.
Apr 7, 2017Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force
Apr 7, 2017Eur J Cancer 2017; 77:127-139
Prior John O, Gillessen Sommer Silke, Wirth Manfred, Dale William, Aapro Matti, Oyen Wim J G